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Key evidence that endogenous nitric oxide (NO) inhibits the continuous, endothelin (ET)-1-
mediated drive to elevate arterial pressure includes demonstrations that ET-1 mediates a
signiﬁcant component of the pressure elevated by acute exposure to NO synthase (NOS)
inhibitors. This review examines the characteristics of this pressure elevation in order to
elucidate potential mechanisms associated with the negative regulation of ET-1 by NO
and, thereby, provide potential insight into the vascular pathophysiology underlying NO
dysregulation. We surmise that the magnitude of the ET-1-dependent component of the
NOS inhibitor-elevated pressure is (1) independent of underlying arterial pressure and other
pressor pathways activated by the NOS inhibitors and (2) dependent on relatively higher
NOS inhibitor dose, release of stored and de novo synthesized ET-1, and ETA receptor-
mediated increased vascular resistance. Major implications of these conclusions include:
(1) the marked variation of the ET-1-dependent component, i.e., from 0 to 100% of the
pressure elevation, reﬂects the NO-ET-1 regulatory pathway.Thus, NOS inhibitor-mediated,
ET-1-dependent pressure elevation in vascular pathophysiologies is an indicator of the level
of compromised/enhanced function of this pathway; (2) NO is a more potent inhibitor of ET-
1-mediated elevated arterial pressure than other pressor pathways, due in part to inhibition
of intravascular pressure-independent release of ET-1.Thus, the ET-1-dependent component
of pressure elevation in vascular pathophysiologies associated with NO dysregulation is of
greater magnitude at higher levels of compromised NO.
Keywords: nitric oxide synthase inhibitor, endothelin-1, arterial blood pressure, endothelin receptor antagonist,
endothelin converting enzyme inhibitor, acute
INTRODUCTION
Amongst the major factors which regulate arterial pressure are the
vasodilator, nitric oxide (NO), and the vasoconstrictor, endothe-
lin (ET)-1 (Lavallée et al., 2001; Bourque et al., 2011). Pressure
regulation by NO and ET-1 is complex and extends beyond their
individual depressor and pressor actions, respectively, due to the
numerous interactions between NO and ET-1. These interactions
include (1) ET-1 release of NO from the vascular endothelium,
mediated by endothelial ETB receptors; (2) NO inhibition of con-
traction to ET-1, the contraction mediated by ETA and/or ETB
receptors (Rapoport and Zuccarello, 2012), and (3) NO inhibition
of ET-1 formation/release (Lavallée et al., 2001; Bourque et al.,
2011).
Not unexpectedly, the relative roles of these different ET-1-NO
interactive mechanisms in the regulation of arterial pressure are
not entirely clear due to the difﬁculty in the differentiation of the
ET-1-NO interactions in vivo. In fact, thesemechanisms are largely
delineated ex vivo and, moreover, through the use of NO donors
and exogenous ET-1 both ex vivo and in vivo (Lavallée et al., 2001;
Bourque et al., 2011).
Although not directly addressing the differential involvement
of these mechanisms in the elevation of arterial pressure, acute
challenge with NO synthase (NOS) inhibitors present a unique
opportunity for the assessment of the overall importance of
endogenous NO in the modulation of the ET-1-mediated drive
to elevate arterial pressure. That is, a component of the NOS
inhibitor-elevation of arterial pressure is ET-1-mediated, as deter-
mined with ET receptor antagonists and an ET converting enzyme
inhibitor (for reviews which incorporated this subject see Lavallée
et al., 2001; Bourque et al., 2011).
Thus, we presently consider that (1) a detailed examination
of the characteristics of the ET-1-dependent, elevated pressure
due to acute challenge with NOS inhibitor may provide an in
vivo context for mechanistic studies directed toward uncover-
ing the intertwined NO and ET-1 pathways in the regulation of
arterial pressure and (2) these characteristics would likely pro-
vide insight into the vascular pathophysiology resulting from NO
dysregulation.
ET-1 AND PRESSURE ELEVATED BY ACUTE NOS INHIBITOR
ET CONVERTING ENZYME INHIBITION
Phosphoramidon, an ET converting enzyme inhibitor, variably
lowered theNOS inhibitor-elevated pressure (Nafrialdi et al., 1994;
Qiu et al., 1995; Gratton et al., 1997; Figure 1). The relative magni-
tude of the phosphoramidon-sensitive to -insensitive component
ranged from approximately half to nearly the total pressure ele-
vated by NOS inhibitor, as determined in rabbit and rat (Nafrialdi
et al., 1994; Qiu et al., 1995; Gratton et al., 1997; Figure 1).
This variability was not due to different efﬁcacies of phospho-
ramidon inhibition of ET converting enzyme in these studies
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FIGURE 1 | Effects of ET converting enzyme inhibitor and ET
receptor antagonist on basal and NOS inhibitor-elevated arterial
pressure. MAP = mean arterial pressure and ETA, ETB, and
ETA/B = ET type A, type B, and A plus B receptor antagonists,
respectively. ↑, ↓, -, n.d., and n.r. signify increased, decreased, no
change, not determined, and not reported, respectively. Dashed arrow
and broken dash represent the directional change and lack of change,
respectively, in NOS inhibitor-elevated pressure by ET receptor
antagonist as compared to NOS inhibitor-elevated basal pressure in the
absence of ET receptor antagonist. Percent inhibitions shown represent
reported values or, if not reported, were estimates. Fink et al. (1998)
utilized stroke-prone spontaneously hypertensive rat.
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since (a) in rabbit, intraventricular 10 mg/kg phosphoramidon
reduced by 88% big ET-1-elevated arterial pressure (Gratton et al.,
1997). Moreover, the considerable phosphoramidon inhibition
of the elevated pressure due to big ET-1 occurred even though
big ET-1 increased pressure by 57 mmHg in comparison to the
NOS inhibitor-elevated pressure of only 17 mmHg (Gratton et al.,
1997); (b) in rat, the phosphoramidon doses (intravenous 10
and 15 mg/kg/h; Nafrialdi et al., 1994; Qiu et al., 1995, respec-
tively) were similar to those used in another rat study in which
the big ET-1-elevated arterial pressure was abolished (Pollock and
Opgenorth, 1991). Basal arterial pressure was also not a factor
in the phosphoramidon reduction of the NOS inhibitor-elevated
elevated pressure since basal pressure was not lowered by phos-
phoramidon (Nafrialdi et al., 1994; Qiu et al., 1995; Gratton et al.,
1997; Figure 1).
ET RECEPTOR ANTAGONISM
ETA and ETA/B receptor antagonist
ETA and ETA/B receptor antagonist also reduced NOS inhibitor-
elevated pressure (Qiu et al., 1995; Richard et al., 1995; Thompson
et al., 1995; Banting et al., 1996; Gardiner et al., 1996; Filep, 1997;
Gellai et al., 1997; Gratton et al., 1997; Fink et al., 1998; Hashimoto
et al., 1998; Ming et al., 1998; Thorin et al., 1999; Montanari et al.,
2000; Kramp et al., 2001; Schmidt et al., 2001; Gomez-Alamillo
et al., 2003; Hubloue et al., 2003; Merkus et al., 2006; Beck et al.,
2007; Czóbel et al., 2009; de Beer et al., 2011; Bourque et al., 2012;
Brochu et al., 2013; Figure 1). In a large majority of these stud-
ies the reduced NOS inhibitor-elevated pressure occurred in the
absence of decreased basal pressure due to ETA/ETA/B recep-
tor antagonist (Qiu et al., 1995; Richard et al., 1995; Thompson
et al., 1995; Banting et al., 1996; Filep, 1997; Gellai et al., 1997;
Gratton et al., 1997; Fink et al., 1998; Thorin et al., 1999; Monta-
nari et al., 2000; Schmidt et al., 2001; Hubloue et al., 2003; Beck
et al., 2007; Figure 1), while in several studies ETA/ETA/B recep-
tor antagonist decreased basal pressure (Hashimoto et al., 1998;
Kramp et al., 2001; Gomez-Alamillo et al., 2003; Merkus et al.,
2006; de Beer et al., 2011; Figure 1). The relative magnitudes
of the ETA/ETA/B receptor antagonist-sensitive component of
the NOS inhibitor-elevated pressure also varied greatly, ranging
from 0 to 100% (Qiu et al., 1995; Richard et al., 1995; Thomp-
son et al., 1995; Banting et al., 1996; Filep, 1997; Gellai et al., 1997;
Gratton et al., 1997; Fink et al., 1998; Thorin et al., 1999; Mon-
tanari et al., 2000; Schmidt et al., 2001; Gomez-Alamillo et al.,
2003; Hubloue et al., 2003; Beck et al., 2007; Czóbel et al., 2009;
Brochu et al., 2013; Figure 1). The variability was not due to the
use of:
(a) ETA versus ETA/B receptor antagonist, since both ETA and
ETA/B receptor antagonist reduced the NOS inhibitor-elevated
pressure to similar magnitudes (Richard et al., 1995; Filep, 1997;
Bourque et al., 2012). Furthermore, ETA/B receptor antagonist
was less efﬁcacious than ETA receptor antagonist in dog (Ming
et al., 1998; Thorin et al., 1999). While the greater inhibitory efﬁ-
cacy of ETA as compared to ETA/B receptor antagonist (Ming
et al., 1998; Thorin et al., 1999) is not entirely clear, one possible
explanation is that ETB receptor antagonism may cause additional
effects that limit the overall ETA receptor reduction of the NOS
inhibitor-elevated pressure.
It should be also be noted, however, that there is some
limited evidence that non-selective ET receptor antagonism is
required to fully expose the ET-1-dependent component of the
NOS-I-elevated pressure. In rat, 10 mg/kg BQ123 (ETA receptor
antagonist) did not decrease the NOS inhibitor-elevated pressure
while 10 mg/kg SB209670 (ETA/B receptor antagonist) inhibited
the elevation by 56% (Gellai et al., 1997). These ﬁndings raise
the possibility that smooth muscle ETB receptors also mediate
the elevated arterial pressure, presumably through ET-1-induced
vasoconstriction. Itmay also be considered that cross-talk between
the ETA and ETB receptors (Rapoport and Zuccarello, 2012) is
responsible for the greater inhibitory effect of ETA/B versus ETA
receptor antagonist (Gellai et al., 1997).
(b) Different species, since amongst dog and rat studies the
reductions of theNOS inhibitor-elevated pressure by ETA/B recep-
tor antagonists both ranged considerably, i.e., from 0 to 100%
(Thorin et al., 1999; Gomez-Alamillo et al., 2003; Hubloue et al.,
2003; Beck et al., 2007) and 23–67% (Qiu et al., 1995; Richard et al.,
1995; Banting et al., 1996; Filep, 1997; Gellai et al., 1997; Fink et al.,
1998), respectively (Figure 1).
(c) Conscious versus anesthetized animals, since in conscious
and anesthetized rat, ETA/B receptor antagonist decreased NOS
inhibitor-elevated arterial pressure by 23–67% (Qiu et al., 1995;
Banting et al., 1996; Filep, 1997; Gellai et al., 1997) and by 40%
and 49% (Richard et al., 1995; Fink et al., 1998), respectively
(Figure 1).
(d) Different doses of ET receptor antagonist, since ET receptor
antagonist doses were generally highly efﬁcacious. Speciﬁcally, in
several studies in which the effects of ET receptor antagonist on
both NOS inhibitor and exogenous ET-1- and big ET-1-elevated
pressure were examined, the ET receptor antagonist greatly inhib-
ited the elevated pressure due to ET-1/big ET-1 even though the
ET-1/big ET-1 dose generally induced a greater increase in pres-
sure than the NOS inhibitor (Thompson et al., 1995; Filep, 1997;
Gratton et al., 1997; Fink et al., 1998; Hubloue et al., 2003; Beck
et al., 2007). However, an untested (to our knowledge) assumption
underlying this comparative analysis of the inhibitory efﬁcacy of
ET receptor antagonist toward the NOS inhibitor- and ET-1-/big
ET-1-elevated pressure is whether ET receptor antagonist efﬁcacy
is reduced by cellular events associated with NOS inhibition.
The possibility that in some studies the dose of ET receptor
antagonist lacked sufﬁcient efﬁcacy should also be considered.
For example, 2 mg/kg BQ123 failed to reduce the NOS inhibitor-
elevated pressure inmouse (Brochu et al., 2013).Whether a greater
BQ123 dose would have reduced the NOS inhibitor-elevated pres-
sure (Brochu et al., 2013) remains a possibility since in rabbit,
in which the NOS inhibitor-elevated pressure peaked and then
decreased somewhat to a maintained level, 10 mg/kg but not
1 mg/kg BQ123 reduced the peak pressure elevation (Gratton
et al., 1997). Also, in rat 10 mg/kg BQ123 failed to reduce the
NOS inhibitor-elevated pressure (Gellai et al., 1997), although in
another study 3 mg/kg BQ123 decreased the elevated pressure by
49% (Richard et al., 1995).
(e) Different doses of NOS inhibitor. Indeed, at successively
greater NOS inhibitor doses, which induced greater magnitudes
of pressure elevation, ET receptor antagonist caused increasingly
larger percent inhibitions of NOS inhibitor-elevated pressure
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(Richard et al., 1995; Filep, 1997; Beck et al., 2007). That is, the
relative ratio of the ET-1-dependent to -independent compo-
nents of the NOS inhibitor-elevated pressure increased with NOS
inhibitor dose and also, therefore, with greater amounts of NOS
inhibitor-induced pressure elevation (Richard et al., 1995; Filep,
1997; Beck et al., 2007). The dose range of the NOS inhibitor, Nω-
nitro-L-arginine methyl ester (L-NAME, intravenous bolus), in rat
was 0.1–3 mg/kg (Richard et al., 1995) and 0.125–2 mg/kg (Filep,
1997), with maximal increased mean arterial pressure achieved at
1 mg/kg. In dog, the dose range of L-NAME (intravenous bolus)
was 0.3–10 mg/kg, with the increase in mean arterial pressure
achieved at 10 mg/kg only slightly greater than that at 3 mg/kg
(Beck et al., 2007).
However, similarmaximally effective (pressure elevation) doses
of L-NAME established in these studies (Richard et al., 1995; Filep,
1997; Beck et al., 2007) were also used in a number of studies,
i.e., 2 mg/kg (Brochu et al., 2013) and 10 mg/kg (Qiu et al., 1995;
Gratton et al., 1997; Fink et al., 1998; Kramp et al., 2001). Fur-
thermore, while other studies used NOS inhibitors other than
L-NAME, i.e., Nω-monomethyl-L-arginine (L-NMMA) and Nω-
nitro-L-arginine (L-NNA), these inhibitors were used at similar
or even greater doses than in the studies with L-NAME. Specif-
ically, L-NMMA was administered at 30 mg/kg (Gardiner et al.,
1996) and 6 mg/kg followed by 3.6 mg/kg/h infusion (in human;
Schmidt et al., 2001), and L-NNA was administered at 4 mg/kg
(Czóbel et al., 2009), 5 mg/kg (Hashimoto et al., 1998), 10 mg/kg
(Gellai et al., 1997), 20 mg/kg (Merkus et al., 2006; de Beer et al.,
2011), and 5 mg/kg followed by 5 mg/kg/h infusion (Hubloue
et al., 2003).
It should be noted that NOS inhibitor was also infused in the
absence of prior intravenous bolus. In animals, L-NAME was
infused over the dose range of 3–12 mg/kg/h (Nafrialdi et al.,
1994; Thompson et al., 1995; Ming et al., 1998; Thorin et al., 1999;
Gomez-Alamillo et al., 2003). In contrast to another human study
(Schmidt et al., 2001, see above), only a relatively low dose of L-
NAME was infused, i.e., 0.18 mg/kg/h (Montanari et al., 2000).
Finally, in two rat studies, L-NAME was injected i.p. at 100 mg/kg
(Banting et al., 1996; Bourque et al., 2012).
ETB receptor antagonist
The effect of ETB receptor antagonist on the NOS inhibitor-
elevated pressure was difﬁcult to evaluate in some studies due
to the increased basal pressure (Gratton et al., 1997; Thorin
et al., 1999; Figure 1). In these studies, ETB receptor antago-
nist failed to alter the NOS inhibitor-elevated pressure (Thorin
et al., 1999) or the pressure was possibly increased (Gratton
et al., 1997). In the one study in which ETB receptor antago-
nist did not alter basal arterial pressure, NOS inhibitor-elevated
pressure remained unaltered by the ETB receptor antagonist
(Kramp et al., 2001).
ET-1 AND BIG ET-1 PLASMA LEVELS
ET-1 plasma levels were inconsistently elevated by NOS inhibitors.
Although elevated ET-1 plasma levels were detected following
acute challenge with NOS inhibitor in the dog, human, and rat, the
increases were of relatively small magnitude (Richard et al., 1995;
Ahlborg and Lundberg, 1997; Filep, 1997; Czóbel et al., 2009).
ET-1 plasma levels were not elevated following NOS inhibitor
in stroke-prone spontaneously hypertensive rat, rabbit, and con-
scious sheep (Tresham et al., 1994; Gratton et al., 1997; Fink et al.,
1998). Also, in the human, while maximal ET-1 plasma levels and
arterial pressure were observed 20 min and 10 min (initial record-
ing) post NOS inhibitor, respectively, ET-1 plasma levels were not
elevated at 30 min post NOS inhibitor even though the pressure
remained elevated (Ahlborg and Lundberg, 1997).
A limited temporal association between elevated ET-1 plasma
levels and NOS inhibitor-elevated arterial pressure was observed
in the dog since both elevated ET-1 plasma levels and elevated
pressure were observed after 15 min infusion with NOS inhibitor
(Czóbel et al.,2009). On theother hand, ETR-P1/ﬂpeptide, anETA
receptor antagonist which purportedly also binds ET-1 (Baranyi
et al., 1995, 1998), completely prevented the increased ET-1 plasma
levels but did not signiﬁcantly reduce and only partially reduced
NOS inhibitor-elevated pressure and -elevated peripheral vascular
resistance, respectively (Czóbel et al., 2009).
The inability to detect NOS inhibitor-elevated ET-1 plasma
levels may be due to clearance of plasma ET-1 by ETB recep-
tors located in the lung and other tissues (de Nucci et al., 1988).
However, elevated ET-1 plasma levels were still not detected in
the rabbit when ETB receptor antagonist was added 10 min after
bolus injection of NOS inhibitor (Gratton et al., 1997). Although,
the detection of elevated ET-1 plasma levels in response to NOS
inhibitor in stroke-prone spontaneously hypertensive rat was
dependent on the presence of an ETA/B receptor antagonist (Fink
et al., 1998). An additional factor that undoubtedly complicates
the detection of elevated plasma ET-1 levels is plasma dilution.
Big ET-1 plasma levels were elevated by intravenous bolus NOS
inhibitor in the rabbit (Gratton et al., 1997). The increase was
transient, with elevated levels at 1 and 2 min which returned to
basal by 10 min (Gratton et al., 1997). Interestingly, ETB receptor
antagonist also elevated big ET-1 levels and, furthermore, NOS
inhibitor prevented this elevation (Gratton et al., 1997).
TIME COURSE OF ELEVATED PRESSURE BY ACUTE NOS
INHIBITOR
The differential effects of ET receptor antagonist and phos-
phoramidon on the phases of NOS inhibitor-elevated pressure
suggest a dependency on different pools of ET-1 (see Con-
clusion/speculations). That is, (a) NOS inhibitor elicited an
initial rapid (minutes) pressure elevation followed by a plateau
phase, as demonstrated with intravenous bolus NOS inhibitor in
mouse (Brochu et al., 2013), rat (Gardiner et al., 1996; Fink et al.,
1998), and rabbit (Gratton et al., 1997), and intraperitoneal NOS
inhibitor in rat (Banting et al., 1996) and (b) ET receptor antag-
onist reduced both the initial rapid phase and plateau phase of
NOS inhibitor-elevated pressure in rat and rabbit (Banting et al.,
1996; Gardiner et al., 1996; Gratton et al., 1997). It should be
noted, however, that ETA/B receptor antagonist did not reduce
the initial rapid phase in the stroke-prone spontaneously hyper-
tensive rat (Fink et al., 1998). Whether the underlying effects of
stroke/hypertension resulted in the apparent ET-1 independence
of the initial phase (Fink et al., 1998) should be considered.
Phosphoramidon (10 mg/kg), in contrast to ET receptor antag-
onist, did not reduce the rapid phase of NOS-elevated pressure in
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rabbit (Gratton et al., 1997). However, the plateau phase of the
pressure elevation was inhibited by phosphoramidon (Gratton
et al., 1997).
INFLUENCE OF PRESSURE/OTHER PRESSOR PATHWAYS
NOS inhibitor-elevated pressure in rat was decreased by com-
bined vasopressin1/2, angiotensin1, and alpha adrenergic receptor
antagonists (Banting et al., 1996), ganglionic blockade and pithing
(Richard et al., 1995), and epidural lidocaine anesthesia (Beck
et al., 2007), while the magnitude of the ET-1-dependent compo-
nent of the NOS inhibitor-elevated pressure remained unaltered.
Indeed, the absolute mmHg reduced by ET receptor antagonist
following ganglionic blockade and pithing was greater than in
untreated rats (Richard et al., 1995). Also of possible relevance is
that ET receptor antagonist did not decrease the elevated arterial
pressure due to angiotensin in rabbit (Gratton et al., 1997) and
phenylephrine in rat (Richard et al., 1995).
The effect of ET receptor antagonist challenge prior versus dur-
ing NOS inhibitor-elevated pressure also reﬂects differences in
pressure elevation. Although numerous studies investigated the
effects of ET receptor antagonist on the NOS inhibitor-elevated
pressure by antagonist addition prior to NOS inhibitor (Richard
et al., 1995; Banting et al., 1996; Filep, 1997; Gellai et al., 1997;
Fink et al., 1998; Hashimoto et al., 1998; Montanari et al., 2000;
Kramp et al., 2001; Gomez-Alamillo et al., 2003; Hubloue et al.,
2003; Beck et al., 2007; Czóbel et al., 2009; Brochu et al., 2013;
Figure 1), or during the NOS inhibitor plateau pressure ele-
vation (Thompson et al., 1995; Banting et al., 1996; Gardiner
et al., 1996; Ming et al., 1998; Thorin et al., 1999; Kramp et al.,
2001; Schmidt et al., 2001; Merkus et al., 2006; de Beer et al.,
2011; Figure 1), only two studies performed both protocols
(Banting et al., 1996; Kramp et al., 2001). Similar magnitudes of
reduction of the NOS inhibitor-elevated pressure were observed
in rat when ET receptor antagonist was added prior to NOS
inhibitor as compared to during the NOS inhibitor plateau pres-
sure elevation (Banting et al., 1996). Furthermore, similar time
periods (∼5 min) were required to achieve plateau pressure ele-
vation following ET receptor antagonist addition prior to NOS
inhibitor and for ET receptor antagonist to reverse the NOS
inhibitor plateau elevation and elicit a lower level of plateau pres-
sure elevation (Banting et al., 1996). While another rat study
also determined the effects of ET receptor antagonist challenge
prior to NOS inhibitor and during the elevated pressure due
to NOS inhibitor, quantiﬁcation of the reductions of the NOS
inhibitor-elevated pressure was difﬁcult due to the lowered basal
arterial pressure by the ET receptor antagonist (Kramp et al.,
2001).
INCREASED VASCULAR RESISTANCE AND ET RECEPTOR
ANTAGONIST
While there is considerable evidence that ET receptor antagonist
inhibits the increased peripheral vascular resistance due to NOS
inhibitor, studies in which the effects of ET receptor antagonist
on both the increased peripheral vascular resistance and on blood
pressure have not been surmized. Indeed, ET receptor antagonist
caused similar percent reductions of NOS inhibitor-elevated pres-
sure and -elevatedperipheral vascular resistance in anesthetized rat
(Thompson et al., 1995) and dog (Gomez-Alamillo et al., 2003).
Also in anesthetized dog, ET receptor antagonist reduced NOS
inhibitor-elevated peripheral vascular resistance by as much as
60% (Czóbel et al., 2009). Although in this study (Czóbel et al.,
2009) the ET receptor antagonist reduction of the NOS inhibitor-
elevated pressure was not statistically signiﬁcant, this lack of
signiﬁcance may be attributed to the relatively large variability
in the pressure measurements.
In possible contrast, in conscious dog, ET receptor antagonist
decreased NOS inhibitor-elevated pressure by 67% while, unex-
pectedly, peripheral vascular resistance was not decreased (Beck
et al., 2007). While the lack of ET receptor antagonist reduc-
tion of the NOS inhibitor-elevated peripheral vascular resistance
might suggest the involvement of other hemodynamic factors, an
effect on NOS inhibitor-induced decreased cardiac output was
apparently not observed (Beck et al., 2007).
Interestingly, in this same study (Beck et al., 2007) but with
dogs subjected to epidural anesthesia, ET receptor antago-
nist decreased the NOS inhibitor-elevated peripheral vascular
resistance and the elevated arterial pressure by 50 and 67%,
respectively.
CONCLUSION/SPECULATIONS
As illustrated in the model of Figure 2, considerable evidence
from studies on the effects of phosphoramidon and ETA and
ETA/ETA/B receptor antagonists on the elevated pressure due
to acute challenge with NOS inhibitor demonstrates that ET-1
mediates a component of the pressure elevation. This component
demonstratesmarked variabilitywhich cannot be accounted for by
numerous experimental parameters. Also, the component is inde-
pendent of other NOS inhibitor-elevated pressure pathways (see
also Lavallée et al., 2001; Bourque et al., 2011). Thus, the variation
reﬂects the overall capacity of the NO-regulated, ET-1-mediated
pathways to elevate pressure.
Another characteristic of the ET-1-dependent component of
the NOS inhibitor-elevated pressure is the apparent dependency
of the pressure elevation on different ET-1 pools, i.e., the initial
rapid phase and plateau phase of pressure elevation may reﬂect
ET-1 release from stored ET-1 and from de novo synthesized
ET-1, respectively. It is important to note that these observations
provide at least indirect in vivo evidence for the involvement of
increased ET-1 release in the NOS inhibitor-elevation of arte-
rial pressure. Indeed, direct support for increased ET-1 release
by NOS inhibitor as evidenced by elevated plasma ET-1 levels is
inconsistent, presumably due to ET-1 clearance and plasma dilu-
tion. Thus, while enhanced ET-1 contraction due to removal of
NO-mediated vasodilatation undoubtedly contributes to the NOS
inhibitor-elevated arterial pressure (Lerman et al., 1992; Xu et al.,
2001; Hocher et al., 2004), ET-1 release represents a contributing
factor.
With respect to the mechanism underlying the increased ET-1
release, several lines of evidence suggest that the release is not
the result of elevated pressure. Indeed, this conclusion also
infers that the component of the NOS inhibitor-elevated pres-
sure attributed to reversal of NO relaxation of smooth muscle
(Banting et al., 1996) also does not trigger ET-1 release. First, low-
ered basal pressure due to inhibition of a number of pressor
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FIGURE 2 | ET-1-dependent and -independent components of the
elevated arterial pressure due to acute NOS inhibitor. (A) Dose-
response: NOS inhibitor (NOS-I) dose and ET-1-independent (dashed line)
and -dependent pressure elevation (solid line). (B) ET-1 pools:
ET-1-dependent component (solid line) consists of an initial rapid and a
subsequent plateau increase in pressure (rightward upward and rightward
downward slanted lines, respectively), which reﬂect dependencies on
stored ET-1 and de novo synthesized ET-1 pools, respectively.
ET-1-independent pressure elevation is indicated by the dashed line.
Squiggled vertical lines indicate varied magnitudes of ET-1-independent and
-dependent components of pressure elevation. See text for further details.
pathways did not decrease the magnitude of the ET-1-dependent
component of NOS inhibitor-elevated pressure. Second, ET
receptor antagonist caused a similar magnitude of inhibition of
the NOS inhibitor-elevated pressure when added prior to NOS
inhibitor addition and during the plateau pressure elevation.
Third, ET receptor antagonist did not reduce the pressure ele-
vated by angiotensin II and phenylephrine (Richard et al., 1995;
Gratton et al., 1997). It should also be considered; however, that
the lack of effect of ET receptor antagonist on pressure due to
these agents (Richard et al., 1995; Gratton et al., 1997) resulted
from increased NO formation, which prevented ET-1 release.
It would be of interest to investigate, therefore, whether ET
receptor antagonist reduction of NOS inhibitor-elevated pressure
is increased in the presence of a pressor agent other than
ET-1.
In any case, themechanismwhereby de novo synthesized ET-1 is
released may be due to reversal of NO inhibition of the conversion
of big ET-1 to ET-1, since NOS inhibitor elevated big ET-1 plasma
levels (Gratton et al., 1997). Furthermore, this regulatory pathway
appears to be shared by ETB receptor-mediated formation of NO,
sinceNOS inhibitor prevented the ETB receptor-mediated increase
in big ET-1 plasma levels (Gratton et al., 1997).
THERAPEUTIC IMPLICATIONS
Based on the independence of the ET-1-dependent compo-
nent of the elevated pressure due to acute challenge with
NOS inhibitor from other pressor systems, it is reasonable
to conclude that the ET-1-dependent effects of NOS inhibi-
tion speciﬁcally reﬂect NO-ET-1 regulatory pathways. Thus,
for example, ET receptor antagonist partial prevention of the
acute NOS inhibitor-elevated pressure in high-salt diet induced
hypertension in bradykinin2 receptor knockout but not wild
type mouse suggests an enhancement of the NO-ET-1 regu-
latory pathway (Brochu et al., 2013; Figure 1). Also, acute
hypoxia may depress the NO-ET-1 regulatory pathway since
hypoxia lowered the magnitude of the NOS inhibitor-elevated,
ET-1-dependent pressure from 61 to 40% (Hubloue et al., 2003;
Figure 1).
Additionally, at least based on a limited number of studies
in which ETA and ETA/ETA/B receptor antagonists were com-
pared head-to-head, the elevated pressure due to NOS inhibitor
appears to result from ET-1 activation of smooth muscle ETA
receptors. Thus, ETA receptor antagonist should effectively reduce
the increased blood pressure that may involve, e.g., endothelial
ETB receptor dysfunction. On the other hand, an ETA/B receptor
antagonist may possess greater therapeutic efﬁcacy in pathologies
in which ETB receptor activation contributes signiﬁcantly to the
pressure elevation.
It should also be noted that the endogenous NOS inhibitor,
asymmetric dimethylarginine, has been implicated in numer-
ous vascular pathologies (Arrigoni et al., 2010; Tamás et al., 2013;
Worthmann et al., 2013). Moreover, these pathologies include con-
ditions in which plasma asymmetric dimethylarginine levels rise
relatively rapidly, such as pre-eclampsia and acute stroke (Arrigoni
et al., 2010; Tamás et al., 2013; Worthmann et al., 2013). Thus,
the in vivo effects of acute NOS inhibitor are highly relevant
with respect to investigations into the altered NO-ET-1 regulatory
pathways in these pathologies.
Finally, based on the observations that the ET-1-dependent
component of the NOS inhibitor-elevated pressure increase with
NOS inhibitor dose (Richard et al., 1995; Filep, 1997; Beck et al.,
2007), it is of interest to speculate that ET receptor antagonist
treatment of pathologies associatedwithNOdysregulation ismore
effective under conditions of greater dysregulation. Whether this
greater efﬁcacy reﬂects increased relative involvement of ET-1
release or enhanced ET-1-induced vasoconstriction requires addi-
tional understanding of the mechanism whereby NO regulates
these pathways.
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